Samil Pharmaceutical Co Ltd

Samil Pharmaceutical's capital structure is highly leveraged, with a debt-to-equity ratio of 1.0, indicating that the company's total liabilities are equal to its total equity. The company's liquidity position is weak, as evidenced by a current ratio of 0.7, suggesting that it may struggle to meet short-term obligations with its current assets. Additionally, the company has negative net cash after subtracting total debt, which raises concerns about its ability to fund operations without external financing.

Profitability metrics for Samil Pharmaceutical are negative, with a return on equity (ROE) of -1.11% and a return on assets (ROA) of -0.47%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets to generate profit. The company's operating income of 2.1 billion KRW is significantly lower than its net loss of 1.74 billion KRW, highlighting the inefficiency in its cost structure or revenue generation.

The company's revenue is concentrated in a single geographic market, South Korea, as no international revenue breakdown is disclosed in the available data. This lack of diversification exposes the company to regional economic and regulatory risks, which could impact its financial stability. No segment-specific revenue data is available, so it is unclear whether the company's operations are diversified across therapeutic areas or product lines.

Samil Pharmaceutical's growth trajectory is uncertain, as the company reported a net loss in the most recent period and has negative operating and free cash flows. Analysts have set a mean price target of 13,000 KRW, which is significantly higher than the current market price of 7,550 KRW, but the lack of strong buy recommendations suggests limited confidence in the company's near-term performance. The company's revenue of 54.3 billion KRW in the latest period does not provide a clear indication of future growth without additional historical data.

The company's risk profile is elevated due to its weak liquidity and negative cash flows. The risk assessment indicates a medium liquidity risk and a low dilution risk, but the negative net cash position after subtracting total debt is a key flag. The company has not issued any recent equity, and there is no indication of dilution pressure in the near term. However, the company's reliance on debt financing could increase its financial risk if interest rates rise or if it faces difficulties in refinancing.

Recent events related to Samil Pharmaceutical include the publication of its latest financial results, which show a net loss and negative cash flows. No recent filings or transcripts are available to provide additional context on the company's strategic direction or operational performance. The lack of detailed disclosures in the financial statements limits the ability to assess the company's long-term prospects.

Samil Pharmaceutical Co Ltd (000520.KS) has undergone a formal classification update, with its economic sector now explicitly identified as Healthcare and its primary activity defined as Pharmaceuticals & Medical Research. This structural clarification, marked as a medium-severity change, establishes the company’s operational context within the broader healthcare industry, providing a clearer framework for sector-specific analysis. Concurrently, the company’s risk profile has been initialized with specific assessments. Dilution risk is now classified as low, indicating a stable capital structure with minimal immediate threat of share value erosion from new issuances. This assessment offers investors a baseline understanding of the equity stability associated with the firm. In contrast, liquidity risk has been assessed at a medium level. This designation suggests that while the company maintains operational viability, there may be moderate constraints or volatility in its ability to meet short-term financial obligations or trade volume expectations. This distinction is critical for evaluating the company’s financial flexibility and market depth. These updates collectively refine the analytical view of Samil Pharmaceutical, moving from an unclassified state to a defined profile within the Healthcare sector. The combination of low dilution risk and medium liquidity risk provides a nuanced starting point for further evaluation of the company’s financial health and market positioning.

Analysts project 108.7% upside to a consensus target price of 13,000 KRW, signaling strong market confidence.

Revenue grew 11.9% year-over-year, demonstrating top-line expansion despite recent profitability challenges in the pharmaceutical sector.

Free cash flow improved by 75.3% year-over-year, indicating better cash generation efficiency compared to the prior period.

Cash conversion ratio of 1.28 exceeds the pharmaceutical cohort median of 0.95, suggesting superior operational cash management.

Capital expenditure intensity is in the top quartile relative to peers, potentially supporting future growth and innovation capabilities.

The company carries a high credit risk flag, raising concerns about its ability to meet financial obligations.

Debt-to-equity ratio of 1.0 is significantly higher than the pharmaceutical cohort median of 0.18, increasing financial leverage risk.

Revenue KRW 210.25B, −4,3% YoY; Operating income −17 496,0% YoY.

• ▍Revenue KRW 210.25B, −4,3% YoY
• ▍Operating income −17 496,0% YoY
• ▍Net income −515,8% YoY
• ▍Free cash flow −569,2% YoY
• ▍Net margin -16.5%

Revenue KRW 179.68B, +33,8% YoY; Operating income +906,0% YoY.

• ▍Revenue KRW 179.68B, +33,8% YoY
• ▍Operating income +906,0% YoY
• ▍Net income +99,5% YoY
• ▍Free cash flow −27,8% YoY
• ▍Net margin -0.0%